Two New Analyses from SEQUOIA-HCM on Effect of Aficamten Between Patients with Mild and Moderate-to-Severe Symptoms, and Across Geographic Regions. HEOR Analyses of Real-World Dat ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 15, 2025 it granted stock options to purchase an aggregate of 40,275 shares of common stock and 27,144 restricted stock units ...

Market forces rained on the parade of Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders today, when the analysts downgraded their forecasts for this year. This report focused on revenue estimates, ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary ...

Cytokinetics has shared positive top-line results from a late-stage study of its investigational oral cardiac myosin ...

Shareholders in Bluebird now have a choice of two offers from would-be acquirers Carlyle and SK Capital. Elsewhere, Cytokinetics shared more aficamten data and BridgeBio started a new kind of Attruby ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Cytokinetics's aficamten outperforms metoprolol in Phase 3 heart disease trial, but FDA approval delayed to December due to ...

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

Cytokinetics said on Tuesday its experimental heart disease drug significantly improved patients' ability to exercise compared to standard-of-care treatment in a late-stage study. The keenly watched ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...